At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, discusses the results of the phase 3 COMBI-d trial which compared the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.
Phase 3 COMBI-d trial of dabrafenib plus trametinib in metastatic
23rd July 2015
Oncology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now